1. Code of Federal Regulations, Title21, Section 312. 21 Phases of an Investigation.
2. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP). Guideline on the Evaluation of Anticancer Medicinal Products in Man. December 2005. Available from http://www.emea.eu.int/pdfs/human/ewp/020595en.pdf. Date of access: 10 August 2006.
3. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Harmonised Tripartite Guideline E4: Dose-Response Information to Support Drug Registration. 10 March 1994. Available from http://www.ich.org/LOB/media/MEDIA480.pdf. Date of access: 10 August 2006.
4. FDA Guidance for Industry (draft). Clinical Trial Endpoints for the Approval of Cancer Drug and Biologics. FDA, April 2005. http://www.fda.gov/cder/Guidance/6592dft.htm. Date of access: 11 August 2006.
5. Dose response studies: I. Some design considerations;Ruberg;Journal of Biopharmaceutical Statistics,1995